188 related articles for article (PubMed ID: 33247544)
1. Adjusting win statistics for dependent censoring.
Dong G; Huang B; Wang D; Verbeeck J; Wang J; Hoaglin DC
Pharm Stat; 2021 May; 20(3):440-450. PubMed ID: 33247544
[TBL] [Abstract][Full Text] [Related]
2. The inverse-probability-of-censoring weighting (IPCW) adjusted win ratio statistic: an unbiased estimator in the presence of independent censoring.
Dong G; Mao L; Huang B; Gamalo-Siebers M; Wang J; Yu G; Hoaglin DC
J Biopharm Stat; 2020 Sep; 30(5):882-899. PubMed ID: 32552451
[TBL] [Abstract][Full Text] [Related]
3. Win statistics (win ratio, win odds, and net benefit) can complement one another to show the strength of the treatment effect on time-to-event outcomes.
Dong G; Huang B; Verbeeck J; Cui Y; Song J; Gamalo-Siebers M; Wang D; Hoaglin DC; Seifu Y; Mütze T; Kolassa J
Pharm Stat; 2023 Jan; 22(1):20-33. PubMed ID: 35757986
[TBL] [Abstract][Full Text] [Related]
4. The net benefit for time-to-event outcome in oncology clinical trials with treatment switching.
Fukuda M; Sakamaki K; Oba K
Clin Trials; 2023 Dec; 20(6):670-680. PubMed ID: 37455538
[TBL] [Abstract][Full Text] [Related]
5. Win-loss parameters for right-censored event data, with application to recurrent events.
Parner ET; Overgaard M
Stat Med; 2023 Dec; 42(30):5723-5735. PubMed ID: 37897052
[TBL] [Abstract][Full Text] [Related]
6. Generalized pairwise comparisons for censored data: An overview.
Deltuvaite-Thomas V; Verbeeck J; Burzykowski T; Buyse M; Tournigand C; Molenberghs G; Thas O
Biom J; 2023 Feb; 65(2):e2100354. PubMed ID: 36127290
[TBL] [Abstract][Full Text] [Related]
7. Robust statistical inference for matched win statistics.
Matsouaka RA
Stat Methods Med Res; 2022 Aug; 31(8):1423-1438. PubMed ID: 35578578
[TBL] [Abstract][Full Text] [Related]
8. Correcting for dependent censoring in routine outcome monitoring data by applying the inverse probability censoring weighted estimator.
Willems S; Schat A; van Noorden MS; Fiocco M
Stat Methods Med Res; 2018 Feb; 27(2):323-335. PubMed ID: 26988930
[TBL] [Abstract][Full Text] [Related]
9. Doubly robust estimator of risk in the presence of censoring dependent on time-varying covariates: application to a primary prevention trial for coronary events with pravastatin.
Kawahara T; Shinozaki T; Matsuyama Y
BMC Med Res Methodol; 2020 Jul; 20(1):204. PubMed ID: 32736528
[TBL] [Abstract][Full Text] [Related]
10. Estimation of treatment effect adjusting for dependent censoring using the IPCW method: an application to a large primary prevention study for coronary events (MEGA study).
Yoshida M; Matsuyama Y; Ohashi Y;
Clin Trials; 2007; 4(4):318-28. PubMed ID: 17848493
[TBL] [Abstract][Full Text] [Related]
11. The stratified win statistics (win ratio, win odds, and net benefit).
Dong G; Hoaglin DC; Huang B; Cui Y; Wang D; Cheng Y; Gamalo-Siebers M
Pharm Stat; 2023; 22(4):748-756. PubMed ID: 36808217
[TBL] [Abstract][Full Text] [Related]
12. The win odds: statistical inference and regression.
Song J; Verbeeck J; Huang B; Hoaglin DC; Gamalo-Siebers M; Seifu Y; Wang D; Cooner F; Dong G
J Biopharm Stat; 2023 Mar; 33(2):140-150. PubMed ID: 35946932
[TBL] [Abstract][Full Text] [Related]
13. Calibration plots for multistate risk predictions models.
Pate A; Sperrin M; Riley RD; Peek N; Van Staa T; Sergeant JC; Mamas MA; Lip GYH; O'Flaherty M; Barrowman M; Buchan I; Martin GP
Stat Med; 2024 Jun; 43(14):2830-2852. PubMed ID: 38720592
[TBL] [Abstract][Full Text] [Related]
14. Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring.
Latimer NR; Abrams KR; Siebert U
BMC Med Res Methodol; 2019 Mar; 19(1):69. PubMed ID: 30935369
[TBL] [Abstract][Full Text] [Related]
15. The stratified win ratio.
Dong G; Qiu J; Wang D; Vandemeulebroecke M
J Biopharm Stat; 2018; 28(4):778-796. PubMed ID: 29172988
[TBL] [Abstract][Full Text] [Related]
16. The win ratio: Impact of censoring and follow-up time and use with nonproportional hazards.
Dong G; Huang B; Chang YW; Seifu Y; Song J; Hoaglin DC
Pharm Stat; 2020 May; 19(3):168-177. PubMed ID: 31671481
[TBL] [Abstract][Full Text] [Related]
17. Evidence synthesis analysis with prioritized benefit outcomes in oncology clinical trials.
Cui Y; Dong G; Kuan PF; Huang B
J Biopharm Stat; 2023 May; 33(3):272-288. PubMed ID: 36343174
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of inferential methods for the net benefit and win ratio statistics.
Verbeeck J; Ozenne B; Anderson WN
J Biopharm Stat; 2020 Sep; 30(5):765-782. PubMed ID: 32097079
[TBL] [Abstract][Full Text] [Related]
19. Augmented and doubly robust G-estimation of causal effects under a Structural nested failure time model.
Mertens K; Vansteelandt S
Biometrics; 2018 Jun; 74(2):472-480. PubMed ID: 28742252
[TBL] [Abstract][Full Text] [Related]
20. The use of the win odds in the design of non-inferiority clinical trials.
Peng L
J Biopharm Stat; 2020 Sep; 30(5):941-946. PubMed ID: 32475213
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
